Resmed Delivers Record FY26 Revenue as Global Sleep Health Demand Remains Strong
Resmed Inc. (ASX: RMD) closed FY26 with strong operating momentum, supported by sustained demand across its sleep devices, masks, accessories and software portfolio. Fourth-quarter revenue increased 9% to a record US$1.46 billion, while non-GAAP diluted earnings per share advanced 16% to US$2.95, reflecting sales growth and improved underlying profitability. For FY26, revenue reached US$5.65 billion, representing 10% growth, while non-GAAP operating margin expanded to 36.1%. The business generated US$1.65 billion in free cash flow during the year, providing capacity to fund innovation, pursue strategic opportunities and enhance shareholder returns. Resmed returned approximately US$1.0 billion through dividends and share repurchases in FY26 and expects to return more than US$1.85 billion in FY27. Strategic initiatives also progressed through the Noctrix Health acquisition, planned MatrixCare divestment and continued international product launches, reinforcing the Company's focus on scalable, technology-enabled sleep and breathing healthcare.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Resmed Delivers Record FY26 Revenue as Global Sleep Health Demand Remains Strong
Resmed Inc. (ASX: RMD) closed FY26 with strong operating momentum, supported by sustained demand across its sleep devices, masks, accessories and software portfolio. Fourth-quarter revenue increased 9% to a record US$1.46 billion, while non-GAAP diluted earnings per share advanced 16% to US$2.95, reflecting sales growth and improved underlying profitability. For FY26, revenue reached US$5.65 billion, representing 10% growth, while non-GAAP operating margin expanded to 36.1%. The business generated US$1.65 billion in free cash flow during the year, providing capacity to fund innovation, pursue strategic opportunities and enhance shareholder returns. Resmed returned approximately US$1.0 billion through dividends and share repurchases in FY26 and expects to return more than US$1.85 billion in FY27. Strategic initiatives also progressed through the Noctrix Health acquisition, planned MatrixCare divestment and continued international product launches, reinforcing the Company's focus on scalable, technology-enabled sleep and breathing healthcare.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au